Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis.

Crocker JC, Ricci-Cabello I, Parker A, Hirst JA, Chant A, Petit-Zeman S, Evans D, Rees S. · 2018

Read Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. by Crocker JC, Ricci-Cabello I, Parker A, Hirst JA, Chant A, Petit-Zeman S, Evans D, Rees S. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6259046.txt.

Introduction

Crocker and co-authors tested whether involving patients and the public helps clinical trials recruit and keep people. Their review and analysis appeared in The BMJ. Involvement can mean patients shaping the question, the design, or the outreach. The team searched ten databases for studies that measured the effect. Twenty-six studies qualified, covering many trial settings.

On average, involvement raised the odds of joining a trial by a modest amount. The clearest gains came when people with lived experience of the condition took part. Their input raised joining odds far more than other forms. Results for keeping members were less firm, with fewer studies to draw on. Extra elements bundled with involvement may share the credit. The authors call for cleaner tests of which forms of involvement work best.

Catalog record

CREATORCrocker JC, Ricci-Cabello I, Parker A, Hirst JA, Chant A, Petit-Zeman S, Evans D, Rees S.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6259046

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis By Joanna C Crocker, Ignacio Ricci-Cabello, Adwoa Parker, Jennifer A Hirst, Alan Chant, Sophie Petit-Zeman, David Evans, Sian Rees Published in: The BMJ DOI: 10.1136/bmj.k4738 ABSTRACT Abstract Objective To investigate the impact of patient and public involvement (PPI) on rates of enrolment and retention in clinical trials and explore how this varies with the context and nature of PPI. Design Systematic review and meta-analysis. Data sources Ten electronic databases, including Medline, INVOLVE Evidence Library, and clinical trial registries. Eligibility criteria Experimental and observational studies quantitatively evaluating the impact of a PPI intervention, compared with no intervention or non-PPI intervention(s), on participant enrolment and/or retention rates in a clinical trial or trials. PPI interventions could include additional non-PPI components inseparable from the PPI (for example, other stakeholder involvement). Data extraction and analysis Two independent reviewers extracted data on enrolment and retention rates, as well as on the context and characteristics of PPI intervention, and assessed risk of bias. Random effects meta-analyses were used to determine the average effect of PPI interventions on enrolment and retention in clinical trials: main analysis including randomised studies only, secondary analysis adding non-randomised studies, and several exploratory subgroup and sensitivity analyses. Results 26 studies were included in the review; 19 were eligible for enrolment meta-analysis and five for retention meta-analysis. Various PPI interventions were identified with different degrees of involvement, different numbers and types of people involved, and input at different stages of the trial process. On average, PPI interventions modestly but significantly increased the odds of participant enrolment in the main analysis (odds ratio 1.16, 95% confidence interval and prediction interval 1.01 to 1.34). Non-PPI components of interventions may have contributed to this effect. In exploratory subgroup analyses, the involvement of people with lived experience of the condition under study was significantly associated with improved enrolment (odds ratio 3.14 v 1.07; P=0.02). The findings for retention were inconclusive owing to the paucity of eligible studies (odds ratio 1.16, 95% confidence interval 0.33 to 4.14), for main analysis). Conclusions These findings add weight to the case for PPI in clinical trials by indicating that it is likely to improve enrolment of participants, especially if it includes people with lived experience of the health condition under study. Further research is needed to assess which types of PPI work best in particular contexts, the cost effectiveness of PPI, the impact of PPI at earlier stages of trial design, and the impact of PPI interventions specifically targeting retention. Systematic review registration PROSPERO CRD42016043808. INTRODUCTION Poor recruitment and retention of patients in trials are major sources of research inefficiency because they delay the delivery of research, inflate its costs, and can lead to biased findings.1 2 The top inefficiency in the conduct of trials from recruitment of the first participant to publication of results is failure to meet recruitment targets.3 Directors of UK clinical trials units have identified “research into methods to boost recruitment in trials” and “methods to minimise attrition” as the top two priorities for trials methodology research.4 In the UK, only 56% of trials funded by the Health Technology Assessment programme recruit their originally specified target sample size, with 32% receiving an extension.5 6 Several initiatives aimed at improving recruitment and retention in clinical trials have been established, including the MRC START research programme and Trial Forge.7 8 Recruitment and retention interventions identified as meriting formal evaluation include patient and public involvement (PPI).9 In the UK, PPI (also known as “public involvement”) has been defined as “research being carried out ‘with’ or ‘by’ members of the public (including patients and carers) rather than ‘to’, ‘about’ or ‘for’ them.”10 Trials in the UK have experienced a recent surge in PPI activity, partly because the National Institute for Health Research (NIHR) now expects active PPI in the research it funds.11 Patients and members of the public are primarily involved in agenda setting, steering committees, ethical review, protocol development, and piloting.12 Many different types of involvement exist, from one person to many people or whole patient organisations, from one-off involvement in a particular aspect of the trial (for example, reviewing draft information for patients or recruiting participants from their communities) to involvement throughout the trial (for example, as members of a trial steering committee), and from involvement with no decision making power (for example, as advisers) to involvement in decision making as equal partners. Two broad arguments are made for involving patients and members of the public in health research: the moral argument (those affected by, or paying for, research should have a say in what and how it is done) and the consequentialist argument (PPI should improve the quality, efficiency, and impact of research). Because clinical trialists and funders are steeped in a predominantly quantitative, evidence based culture, the consequentialist argument for PPI in clinical trials (for example, that it increases participant enrolment rates) is likely to play an important role in the adoption of meaningful PPI as routine, widespread practice. Hypotheses about how PPI could increase enrolment rates include greater access to potential participants, improved information sheets, more patient centred trial design, more relevant research questions, and peer endorsement of research.13 14 15 16 One observational study of 114 trials reported a doubled odds of successful recruitment associated with “consumer input,” but this did not attain statistical significance (odds ratio 2.00, 95% confidence interval 0.36 to 10.05).17 A more recent observational study reported a statistical association between PPI and success of recruitment among UK mental health research studies,13 but many potential confounding factors could not be controlled for, and information about the nature of PPI in the included studies was lacking. Exploring the effectiveness of PPI practices to improve recruitment and retention of trial participants has been identified as one of the top research priorities for PPI in trials.18 This review aimed to measure the impact of PPI interventions on recruitment (specifically participant enrolment) and retention in clinical trials. A secondary objective was to explore how this impact varies according to context (for example, patient population, recruitment setting, trial treatment/intervention) and the nature of the PPI intervention (for example, activities, involvement model, and other PPI characteristics). METHODS Searches Our systematic literature review followed the PRISMA statement.19 We did a systematic electronic search in the following databases (last updated October 2017): Medline, Science Citation Index, Social Science Citation Index, Embase, PsychINFO, Cochrane Library, CINAHL, and Health Expectations journal. We constructed the search strategy by combining keywords within four topic domains: clinical trials, PPI, enrolment or retention of participants, and potential outcomes/change (see appendix 1). In addition to the electronic database search, we searched the INVOLVE Evidence Library for any papers pertaining to the impact of public involvement on health or public health research,20 as well as the ClinicalTrials.gov and WHO ICTRP clinical trial registries. Screening and study selection We conceptualised PPI as a complex intervention,21 involving human behaviours and often multiple interactive components. We included papers that quantitatively evaluated the impact of a PPI intervention, compared with no intervention or another non-PPI intervention, on enrolment and/or retention rates in a clinical trial or trials in any patient population (see eligibility criteria in

Read the complete text